PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Latest Episodes:

Stephen V. Liu, MD - Amplifying the ADC Advantage: How to Fulfill the Potential of Antibody–Drug Conjugates as the Next Frontier in Precision Lung Cancer Care Jul 28, 2023

Show notes

Go online to PeerView.com/YEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research settings to clinical practice, with the first approval of a novel HER2-targeting ADC, trastuzumab deruxtecan, for HER2-mutated NSCLC. In addition, various other potent ADCs targeting HER3, TROP2, CEACAM5, c-MET, AXL, ROR2, and others are being evaluated in clinical trials in different disease settings, including in patients with advanced NSCLC with and without actionable genomic alterations, and they are showing impressive activity. How do we realize the promise of these ADCs as the next frontier in precision lung cancer care? What are the best ways to apply the emerging science to patient care decisions in everyday practice? These and other key questions are addressed in this activity, which is based on a recent live symposium and produced in collaboration with the LUNGevity Foundation to highlight patient perspectives alongside those of clinicians. Leading experts in the field share their interpretations of the latest practice-changing evidence and provide practical guidance using real-world case scenarios to demonstrate how to maximize beneficial patient outcomes using ADCs. Upon completion of this activity, participants should be better able to: Discuss the modern composition, rationale for use, and clinical potential of novel ADCs in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of novel ADCs in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including novel ADCs; and Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life

Rohit Loomba, MD, MHSc - Hope Is on the Horizon for Nonalcoholic Steatohepatitis: Leveraging the Power of Next Generation Monitoring and Pharmacotherapies Jul 28, 2023

Show notes

Go online to PeerView.com/RVV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hepatology discusses NAFLD and NASH as metabolic diseases and potential therapeutic targets for patients with the conditions. Upon completion of this activity, participants should be better able to: Describe the disease pathways and mechanisms that define NAFLD/NASH as metabolic diseases; Discuss the pathophysiology and role of GLP-1 as a therapeutic target in NAFLD/NASH and other metabolic conditions; Use noninvasive tests and biomarkers to monitor NAFLD/NASH disease progression; and Initiate early guideline-driven and pathway-driven management with available and emerging pharmacotherapies to delay NAFLD/NASH progression and improve outcomes for patients

Guillermo Garcia-Manero, MD - The Team Takes Command in MDS: Guidance on Diagnostic and Treatment Principles for Risk-Based Care and Beyond Jul 28, 2023

Show notes

Go online to PeerView.com/TVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Rapid change is coming to the management of myelodysplastic syndromes (MDS), fueled by new science that will expand the therapeutic possibilities for managing different patient populations and impact the management team. But are you ready to be a team player and help revolutionize MDS care? Find out by viewing this PeerView “Clinical Consults” activity based on a symposium held during the 2023 ASCO Annual Meeting. Watch as an expert panel provides insights on the use of innovative therapies for the first-line management of MDS anemia, the treatment of ESA-refractory patients, and management of patients presenting with high-risk disease. Throughout, they will also provide practical insights for effective delivery of care, including patient education, appropriate dosing, and adverse event management. Don’t miss this opportunity to see how your team can take command of care when managing your patients with MDS! Upon completion of this activity, participants should be better able to: Discuss molecular and pathologic features, risk factors, and clinical signs that can inform a timely team-based diagnostic and prognostic assessment of MDS; Cite clinical evidence supporting the use of innovative therapeutics with unique mechanisms of action for the management of patients with low-risk or high-risk MDS; Develop risk-adapted team management of protocols for patients with MDS, including for the first-line management of anemia, in the ESA-failing setting, or for patients presenting with higher-risk genomic subtypes; and Recommend team-based strategies to manage therapy delivery considerations in the MDS setting, including selection of appropriate dosing, response monitoring, and management of therapy-related adverse events

Robert Z. Orlowski, MD, PhD - The New ABCs of Myeloma Care: Enhancing Outcomes With CD38 Antibodies, BCMA Immunotherapy, and Unique Bispecific Platforms Jul 28, 2023

Show notes

Go online to PeerView.com/HZN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The expanding use of CD38 antibodies, CAR-T, and BCMA and non-BCMA treatment options has quickly changed the clinical conversation for modern multiple myeloma (MM) management. Are you prepared for the new “ABCs” of myeloma care? Find out by accessing this PeerView MasterClass and Case Forum event developed in collaboration with the HealthTree Foundation for Multiple Myeloma and recorded at the 2023 ASCO Annual Meeting. During this activity, our experts provide insights and case-based guidance on therapy selection, dosing, scheduling, and management of treatment-related AEs with CD38 antibodies and BCMA platforms in MM. Learn the real-world “ABCs” of treatment innovation in MM, and take your patient care to the next level! Upon completion of this activity, participants should be better able to: Summarize the unique MOA and safety/efficacy evidence supporting the use of CD38 and BCMA-targeting antibodies, CAR-T therapy, and other innovative compounds across multiple myeloma treatment settings; Develop personalized upfront and sequential treatment plans with innovative antibody and immunotherapy platforms, based on relevant prognostic information and safety considerations; and Address practical aspects of multiple myeloma care when using antibody and immunotherapy platforms, including dosing, scheduling, patient referral to specialized care, education, counseling, and unique treatment-related toxicities

Athena Philis-Tsimikas, MD - Episode 4: Exploring Therapeutic Potential of Once-Weekly Basal Insulin Therapy Jul 24, 2023

Show notes

Go online to PeerView.com/KNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is indispensable to the treatment of diabetes, but its use in people with diabetes presents numerous well-known challenges. As many as 40% of people with T2DM require insulin therapy, but only about one-third initiate basal insulin. How can endocrinologists and other healthcare providers ease the treatment burden for these patients? Part of the answer may lie in once-weekly basal insulins. This PeerView inQuiry challenges you to examine the role of once-weekly basal insulins and how they may help to improve outcomes in patients with diabetes. Four assessment questions will keep you on your toes, and an expert will share short, authoritative explanations on the latest clinical data, rationale for use, dosing and tips and strategies for helping patients achieve glycemic targets with less frequent basal insulin injection. Upon completion of this activity, participants should be better able to: Compare the efficacy, safety, administration, and dosing frequency of once-weekly with once-daily basal insulins; and Identify patients with T2DM that are not meeting individualized glycemic goals and who may benefit from basal insulin therapy, including once-weekly formulations, as they become available

Athena Philis-Tsimikas, MD - Episode 3: Practical Considerations for Once-Weekly Basal Insulin Therapy Jul 24, 2023

Show notes

Athena Philis-Tsimikas, MD - Episode 2: Overcoming Clinical Inertia in Patients With T2DM Jul 24, 2023

Show notes

Athena Philis-Tsimikas, MD - Episode 1: Current Guidance and Indications for Basal Insulin in Patients With T2DM Jul 24, 2023

Show notes

Allison Agwu, MD, ScM, FAAP, FIDSA - Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider Jul 06, 2023

Show notes

Go online to PeerView.com/GRT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum. Upon completion of this activity, participants should be better able to: Identify individual and structural factors that contribute to PLWH falling out of care; Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care; and Employ individualized and comprehensive plans to successfully re-engage PLWH in care

Martina J. Porter, MD - How Do You Diagnose and Treat Hidradenitis Suppurativa? Compare Your Approach With the Experts’ Jul 06, 2023

Show notes

Go online to PeerView.com/MYV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hidradenitis suppurativa (HS) is a chronic and recurrent inflammatory dermatologic condition that can take a long time to diagnose because of its relative rarity and long list of differential diagnoses. In the meantime, the pain and embarrassment caused by discharge and disfiguration severely decrease the quality of life for people who are impacted. Fortunately, there are a number of biologic therapies that are approved to treat HS or are in Phase 2 and 3 trials, such as inhibitors of IL-1, IL-17F and IL-17A. This activity is designed to reduce the time to diagnosis, educate clinicians on the burden their patients face, and understand the need for emerging therapies with greater efficacy. Two faculty experts will walk you through HS management and treatment protocols, with a focus on improving your knowledge and competence to incorporate new and emerging therapies into the management of this complex disease. Upon completion of this activity, participants should be better able to: Identify signs, symptoms, and diagnostic challenges to make a timely and accurate diagnosis of hidradenitis suppurativa; Describe the burdens of disease and impact on quality of life for patients with hidradenitis suppurativa; Recognize the limitations of current therapies for hidradenitis suppurativa; and Apply clinical safety and efficacy data on emerging novel treatments for patients with hidradenitis suppurativa

Our TOPPODCAST Picks

Follow Us

Stay Connected

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Related Podcasts

Links

Stay Connected